ReviewCurrent topics in microbiology and immunology2026
Antiviral Strategies Against Dengue Virus: Recent Insights into Compounds Targeting Viral and Host Factors.
Review in Current topics in microbiology and immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dengue Virus NS5 Target Discovery: A Comprehensive in Silico Exploration of Novel Druggable Sites for Pan-Serotype Antiviral Design.International journal of molecular sciences · 2026Article
- The inhibition mechanism ofFrontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue virus (DENV), the most prevalent arbovirus worldwide, continues to pose a major public health threat with no approved antiviral therapy to date. Despite decades of research, therapeutic development remains stalled at the preclinical stage, hindered by the virus's genetic variability, narrow therapeutic window, and complex interplay with the host immune system. This review offers a comprehensive overview of current antiviral strategies, covering both direct-acting antivirals (DAAs) targeting viral proteins (E, prM/M, C, NS2B/NS3, NS4A/B, and NS5) and host-targeting antivirals (HTAs) interfering with viral entry, replication, assembly, and immune modulation. Across 11 mechanistic categories, we observe a strong prevalence of natural products with in vitro efficacy, but limited advancement to in vivo or clinical testing. This translational gap reflects key limitations: restricted compound availability, lack of pharmacokinetic data, and insufficient collaboration between pharmacognosy, virology, and medicinal chemistry. We highlight the urgent need for integrated efforts to optimize promising leads and promote their clinical development. This review outlines the main challenges and perspectives to reinvigorate antiviral discovery against DENV.
Indexed as
Identifiers
40879683What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.